



Marinus Pharmaceuticals
Investor Relations Department
170 N. Radnor Chester Road,
Suite 250
Radnor, PA 19087-5279
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: MRNS

Last Trade:	7.90
Trade Time:	3:06 PM ET Jan 23, 2018
Change:	0.35 ▲ (+4.636%)
Day Range	7.22 - 8.11
52-Week Range	1.13 - 9.87
Volume	1,470,278


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 13, 2017

[Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index](#)

Oct 31, 2017

[Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results](#)

Sep 21, 2017

[Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

Sep 19, 2017

[Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares](#)

Sep 15, 2017

[Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock](#)

Upcoming Events [\[View all \]](#)

Feb 14, 2018

[Leerink Partners 7th Annual Global Healthcare Conference](#)

Feb 21–22, 2018

[RBC Capital Markets Global Healthcare Conference](#)

Financials & Filings [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Mar 16, 2017

[Proxy Statement \(DEF 14A\)](#)

Oct 31, 2017

[Quarterly Report \(10-Q\)](#)

Aug 1, 2017

[Quarterly Report \(10-Q\)](#)

May 1, 2017

[Quarterly Report \(10-Q\)](#)